Loading patent…
AssigneesRibomic Inc., Cellmid Limited
InventorsAkio Suzumura, Jinyan Wang, Takashi Matsui, Sadatoshi Sakuma, Shin Miyakawa, Masatoshi Fujiwara, Yoshikazu Nakamura
Estimating the term…
The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.
A method for increasing a number of regulatory CD4-positive, CD25-positive T cells in a subject having multiple sclerosis, said method comprising administering a midkine (MK) inhibitor to a subject having multiple sclerosis to thereby expand said regulatory T cell population in said subject, wherein the MK inhibitor is an antibody that binds to an MK protein comprising the amino acid sequence of SEQ ID NO:
A method for the treatment of multiple sclerosis, said method comprising administering a midkine (MK) inhibitor to a subject having multiple sclerosis, wherein the MK inhibitor is an antibody that binds to an MK protein comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.